Marcy L'Etoile, France - September 6, 2011.
Operating income before non-recurring items
- Up 5.2%
- At 17.8% of sales
Two strategic acquisitions:
- AES Laboratoire, making bioMérieux world leader in food testing
- ARGENE, specialized in molecular diagnostics for immunocompromised patients
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met today to approve the consolidated financial statements for the six months ended June 30, 2011. The meeting was chaired by Jean-Luc Bélingard and attended by the Statutory Auditors, who had performed a limited review of the financial statements.
Download
- Filename
- pr_biomerieux_h1_2011_results.pdf
- Size
- 64 KB
- Format
- application/pdf